Selena Z Kuo1, Katja Dettmer2, Medini K Annavajhala3, David H Chong4, Anne-Catrin Uhlemann3, Julian A Abrams5, Peter J Oefner2, Daniel E Freedberg6. 1. Department of Medicine, Columbia University Medical Center, New York, NY, USA. Electronic address: szk9009@nyp.org. 2. Institute of Functional Genomics, University of Regensburg, Regensburg, Germany. 3. Department of Medicine, Division of Infectious Diseases and Microbiome & Pathogen Genomics Core, Columbia University Medical Center, New York, NY, USA. 4. Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY, USA. 5. Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA. 6. Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, NY, USA. Electronic address: def2004@cumc.columbia.edu.
Abstract
PURPOSE: 3-indoxyl sulfate (3-IS) is an indole metabolism byproduct produced by commensal gut bacteria and excreted in the urine; low urinary 3-IS has been associated with increased mortality in bone marrow transplant recipients. This study investigated urinary 3-IS and patient outcomes in the ICU. MATERIALS AND METHODS: Prospective study that collected urine samples, rectal swabs, and clinical data on 78 adult ICU patients at admission and again 72 h later. Urine was analyzed for 3-IS by mass spectrometry. RESULTS: Median urinary 3-IS levels were 17.1 μmol/mmol creatinine (IQR 9.5 to 26.2) at admission and 15.6 (IQR 4.2 to 30.7) 72 h later. 22% of patients had low 3-IS (≤6.9 μmol/mmol) on ICU admission and 28% after 72 h. Low 3-IS at 72 h was associated with fewer ICU-free days (22.5 low versus 26 high, p = 0.03) and with death during one year of follow-up (36% low versus 9% high 3-IS, p < 0.01); there was no detectable difference in 30-day mortality (18% low versus 5% high, p = 0.07). CONCLUSIONS: Low urinary 3-IS level 72 h after ICU admission was associated with fewer ICU-free days and with increased one-year but not 30-day mortality. Further studies should investigate urinary 3-IS as an ICU biomarker.
PURPOSE: 3-indoxyl sulfate (3-IS) is an indole metabolism byproduct produced by commensal gut bacteria and excreted in the urine; low urinary 3-IS has been associated with increased mortality in bone marrow transplant recipients. This study investigated urinary 3-IS and patient outcomes in the ICU. MATERIALS AND METHODS: Prospective study that collected urine samples, rectal swabs, and clinical data on 78 adult ICU patients at admission and again 72 h later. Urine was analyzed for 3-IS by mass spectrometry. RESULTS: Median urinary 3-IS levels were 17.1 μmol/mmol creatinine (IQR 9.5 to 26.2) at admission and 15.6 (IQR 4.2 to 30.7) 72 h later. 22% of patients had low 3-IS (≤6.9 μmol/mmol) on ICU admission and 28% after 72 h. Low 3-IS at 72 h was associated with fewer ICU-free days (22.5 low versus 26 high, p = 0.03) and with death during one year of follow-up (36% low versus 9% high 3-IS, p < 0.01); there was no detectable difference in 30-day mortality (18% low versus 5% high, p = 0.07). CONCLUSIONS: Low urinary 3-IS level 72 h after ICU admission was associated with fewer ICU-free days and with increased one-year but not 30-day mortality. Further studies should investigate urinary 3-IS as an ICU biomarker.
Authors: Jens U Jensen; Lars Hein; Bettina Lundgren; Morten H Bestle; Thomas T Mohr; Mads H Andersen; Klaus J Thornberg; Jesper Løken; Morten Steensen; Zoe Fox; Hamid Tousi; Peter Søe-Jensen; Anne Ø Lauritsen; Ditte Strange; Pernille L Petersen; Nanna Reiter; Søren Hestad; Katrin Thormar; Paul Fjeldborg; Kim M Larsen; Niels E Drenck; Christian Ostergaard; Jesper Kjær; Jesper Grarup; Jens D Lundgren Journal: Crit Care Med Date: 2011-09 Impact factor: 7.598
Authors: J L Vincent; A de Mendonça; F Cantraine; R Moreno; J Takala; P M Suter; C L Sprung; F Colardyn; S Blecher Journal: Crit Care Med Date: 1998-11 Impact factor: 7.598
Authors: Philipp Schuetz; Robert Birkhahn; Robert Sherwin; Alan E Jones; Adam Singer; Jeffrey A Kline; Michael S Runyon; Wesley H Self; D Mark Courtney; Richard M Nowak; David F Gaieski; Stefan Ebmeyer; Sascha Johannes; Jan C Wiemer; Andrej Schwabe; Nathan I Shapiro Journal: Crit Care Med Date: 2017-05 Impact factor: 7.598
Authors: Alexandra E Livanos; Erik J Snider; Susan Whittier; David H Chong; Timothy C Wang; Julian A Abrams; Daniel E Freedberg Journal: PLoS One Date: 2018-08-01 Impact factor: 3.240
Authors: Alexander Zaborin; Daniel Smith; Kevin Garfield; John Quensen; Baddr Shakhsheer; Matthew Kade; Matthew Tirrell; James Tiedje; Jack A Gilbert; Olga Zaborina; John C Alverdy Journal: mBio Date: 2014-09-23 Impact factor: 7.867